{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T22:06:30Z","timestamp":1767909990697,"version":"3.49.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,3,24]],"date-time":"2016-03-24T00:00:00Z","timestamp":1458777600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.jbo.2016.03.002","type":"journal-article","created":{"date-parts":[[2016,4,29]],"date-time":"2016-04-29T14:18:38Z","timestamp":1461939518000},"page":"90-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Bone targeted treatments in cancer \u2013 The story so far"],"prefix":"10.1016","volume":"5","author":[{"given":"Robert","family":"Coleman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3899","key":"10.1016\/j.jbo.2016.03.002_bib1","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1126\/science.165.3899.1264","article-title":"Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo","volume":"165","author":"Francis","year":"1969","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.jbo.2016.03.002_bib2","doi-asserted-by":"crossref","first-page":"919","DOI":"10.2165\/00003495-199142060-00003","article-title":"Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease","volume":"42","author":"Fleisch","year":"1991","journal-title":"Drugs"},{"issue":"8344","key":"10.1016\/j.jbo.2016.03.002_bib3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0140-6736(83)90231-3","article-title":"Comparison of intravenous (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate and volume repletion in tumour-induced hypercalcaemia","volume":"2","author":"Sleeboom","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.jbo.2016.03.002_bib4","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/bjc.1987.225","article-title":"3(amino-1.1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer","volume":"56","author":"Coleman","year":"1987","journal-title":"Br. J. Cancer"},{"issue":"17","key":"10.1016\/j.jbo.2016.03.002_bib5","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1001\/archinte.1994.00420170079008","article-title":"Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone","volume":"154","author":"Gucalp","year":"1994","journal-title":"Arch. Intern. Med."},{"issue":"8317","key":"10.1016\/j.jbo.2016.03.002_bib6","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0140-6736(83)92755-1","article-title":"Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases","volume":"1","author":"Elomaa","year":"1983","journal-title":"Lancet"},{"issue":"8566","key":"10.1016\/j.jbo.2016.03.002_bib7","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(87)92555-4","article-title":"Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment","volume":"2","author":"van Holten-Verzantvoort","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.jbo.2016.03.002_bib8","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/bjc.1988.272","article-title":"Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1.1-biphosphonate (APD)","volume":"58","author":"Coleman","year":"1988","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jbo.2016.03.002_bib9","first-page":"2","article-title":"Bisphosphonates for the relief of pain secondary to bone metastases","author":"Wong","year":"2002","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jbo.2016.03.002_bib10","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma","volume":"334","author":"Berenson","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbo.2016.03.002_bib11","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.1998.16.6.2038","article-title":"Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate: Protocol 19 Aredia Breast Cancer Study Group","volume":"16","author":"Hortobagyi","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2016.03.002_bib12","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1200\/JCO.1999.17.3.846","article-title":"Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group","volume":"17","author":"Theriault","year":"1999","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jbo.2016.03.002_bib13","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1200\/JCO.1993.11.1.59","article-title":"Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer","volume":"11","author":"Paterson","year":"1993","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2016.03.002_bib14","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in treatment of skeletal complications in patients with advanced multiple myeloma or breast cancer: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2016.03.002_bib15","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with advanced prostate cancer and bone metastasis","volume":"96","author":"Saad","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jbo.2016.03.002_bib16","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non small cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2016.03.002_bib17","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomized controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jbo.2016.03.002_bib18","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrd3705","article-title":"Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab","volume":"11","author":"Lacey","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jbo.2016.03.002_bib19","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic Acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2016.03.002_bib20","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jbo.2016.03.002_bib21","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"Suppl 3","key":"10.1016\/j.jbo.2016.03.002_bib22","doi-asserted-by":"crossref","first-page":"Siii124","DOI":"10.1093\/annonc\/mdu103","article-title":"Bone health in cancer patients: ESMO clinical practice guidelines","volume":"25","author":"Coleman","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jbo.2016.03.002_bib23","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/jnci\/djs263","article-title":"Effects of bone-targeted agents on cancer progression and mortality","volume":"104","author":"Coleman","year":"2012","journal-title":"J. Nat. Cancer Inst."},{"key":"10.1016\/j.jbo.2016.03.002_bib24","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S1470-2045(15)00489-1","article-title":"Addition of docetaxel or bisphosphonate to standard of care in men with localized or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data","volume":"17","author":"Vale","year":"2016","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.jbo.2016.03.002_bib25","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/1758834015582178","article-title":"Bone-targeted agents in the treatment of lung cancer","volume":"7","author":"Silva","year":"2015","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.jbo.2016.03.002_bib26","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1093\/annonc\/mdn429","article-title":"Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up","volume":"19","author":"Diel","year":"2008","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jbo.2016.03.002_bib27","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1186\/bcr1384","article-title":"Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]","volume":"8","author":"Powles","year":"2006","journal-title":"Breast Cancer Res.: BCR"},{"key":"10.1016\/j.jbo.2016.03.002_bib28","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1470-2045(12)70226-7","article-title":"Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial","volume":"13","author":"Paterson","year":"2012","journal-title":"Lancet oncol."},{"key":"10.1016\/j.jbo.2016.03.002_bib29","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbo.2016.03.002_bib30","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","article-title":"Breast-cancer adjuvant therapy with zoledronic acid","volume":"365","author":"Coleman","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbo.2016.03.002_bib31","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1158\/1078-0432.CCR-13-1246","article-title":"Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo","volume":"20","author":"Ottewell","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"10001","key":"10.1016\/j.jbo.2016.03.002_bib32","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(15)60908-4","article-title":"Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials","volume":"386","author":"Early Breast Cancer Clinical Trials Collaborative Group (EBCTCG)","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jbo.2016.03.002_bib33","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/annonc\/mdv617","article-title":"Adjuvant bisphosphonates in early breast cancer: Consensus guidance for clinical practice from a European Panel","volume":"27","author":"Hadji*","year":"2016","journal-title":"Ann. Oncol."},{"issue":"9810","key":"10.1016\/j.jbo.2016.03.002_bib34","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jbo.2016.03.002_bib35","unstructured":"M. Gnant, G. Pfeiler, P.C. Dubsky, M. Hubalek, et al. The impact of adjuvant denosumab on disease-free survival: Results from 3425 postmenopausal patients of the ABCSG-18 trial. in: Proceedings of the San Antonio Breast Cancer Symposium (SABCS) 2015: Abstract S2-02. Presented December 10, 2015."},{"key":"10.1016\/j.jbo.2016.03.002_bib36","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/annonc\/mds277","article-title":"Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results","volume":"24","author":"Coleman","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jbo.2016.03.002_bib37","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","article-title":"Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"386","author":"Gnant","year":"2015","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jbo.2016.03.002_bib38","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbo.2016.03.002_bib39","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.jbo.2016.03.002_bib40","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1053\/j.semnuclmed.2015.10.012","article-title":"Treatment of metastatic bone disease and the emerging role of radium-223","volume":"46","author":"Coleman","year":"2016","journal-title":"Semin. Nucl. Med."},{"issue":"6","key":"10.1016\/j.jbo.2016.03.002_bib41","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1186\/s13058-014-0484-9","article-title":"Role of bone-anabolic agents in the treatment of breast cancer bone metastases","volume":"16","author":"Suvannasankha","year":"2014","journal-title":"Breast Cancer Res."}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137416300276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137416300276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:15:36Z","timestamp":1761941736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137416300276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S2212137416300276"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2016.03.002","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bone targeted treatments in cancer \u2013 The story so far","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2016.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Author. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}]}}